Charbel Issa Peter, Scholl Hendrik P N, Holz Frank G
From the Department of Ophthalmology, University of Bonn, Germany.
Retin Cases Brief Rep. 2007 Fall;1(4):189-91. doi: 10.1097/ICB.0b013e31809ed9b6.
To report the effect of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia (type 2 IMT).
Interventional case report.
A 51 year-old female patient with type 2 IMT presented with gradual visual deterioration and reading difficulties. In one affected eye, two intravitreal bevacizumab injections were performed with a four weeks interval. Examinations included ETDRS visual acuity, slit-lamp biomicroscopy, digital fluorescein angiography, optical coherence tomography (OCT) and microperimetry at baseline and during a 12-week review period.
Following treatment the patient noted a visual improvement particularly during reading. On angiography a reduction in size and intensity of the hyperfluorescent area was recorded and the retinal sensitivity improved on microperimetry.
In absence of other efficacious therapeutic modalities, the observations indicate a beneficial therapeutic effect of intravitreal bevacizumab in type2-IMT, and implicate a pathophysiological role of VEGF in this disease entity.
报告玻璃体内注射贝伐单抗治疗2型特发性黄斑毛细血管扩张症（2型IMT）的效果。
介入性病例报告。
一名患有2型IMT的51岁女性患者出现视力逐渐下降和阅读困难。在一只患眼中，每隔四周进行两次玻璃体内贝伐单抗注射。检查包括ETDRS视力、裂隙灯生物显微镜检查、数字荧光血管造影、光学相干断层扫描（OCT）以及基线和12周复查期间的微视野检查。
治疗后患者注意到视力有所改善，尤其是在阅读时。血管造影显示高荧光区域的大小和强度减小，微视野检查显示视网膜敏感度提高。
在缺乏其他有效治疗方式的情况下，这些观察结果表明玻璃体内注射贝伐单抗对2型IMT有有益的治疗效果，并提示VEGF在该疾病实体中的病理生理作用。
